We provide full-turnkey design and build services for GMP-compliant mRNA vaccine manufacturing facilities, covering plasmid DNA production, in vitro transcription, mRNA purification, LNP encapsulation, sterile formulation and final filling workflows. Tailored for both clinical pilot production and large-scale commercial vaccine industrialization, our integrated engineering solutions fully comply with FDA cGMP, EU GMP and ISO 14644 cleanroom and biomanufacturing specifications. Adopting mRNA-specific contamination control and molecular stability design principles, we deliver fully audit-ready, process-optimized manufacturing plants adapted to the high-precision, low-degradation requirements of nucleic acid vaccine production.
Our mRNA vaccine facility design features process-driven functional zoning and ultra-stable environmental control customized for sensitive nucleic acid materials. We implement strictly segregated production zones for plasmid amplification, mRNA synthesis, purification, LNP formulation and sterile finishing, establishing complete unidirectional flow for personnel, materials and waste to eliminate cross-contamination and exogenous nucleic acid pollution risks. Graded ISO 5 to ISO 8 cleanroom classification, precise humidity and temperature locking, independent sterile gas supply and low-turbulence airflow systems effectively prevent mRNA degradation and LNP particle aggregation. Specialized RNase-free structural and pipeline design ensures ultra-high cleanliness throughout the entire vaccine manufacturing workflow.
Covering full-lifecycle design and build turnkey delivery, our service scope includes project feasibility assessment, mRNA process-based master layout planning, cleanroom structural design and construction, full MEP and utility system integration, RNase-free sanitary pipeline deployment, process equipment skid matching, on-site installation, system commissioning and complete GMP validation document support. All production contact surfaces adopt high-precision dead-zone-free polishing design with full CIP and SIP compatibility, supporting reliable repeated aseptic batch production. Intelligent full-process data monitoring and traceability systems fully meet global regulatory audit and vaccine batch release standards.
Empowered by professional mRNA biomanufacturing engineering experience, our design and build solutions address the core industry challenges of strict RNase control, fragile molecular stability and high process reproducibility requirements. Highly specialized facility architecture stabilizes vaccine production quality, minimizes batch deviation and reduces product loss rates. Modular and scalable construction modes support flexible capacity expansion and rapid process iteration to adapt to updated vaccine variants and new formula upgrades. We help biotech and pharmaceutical enterprises build compliant, stable and future-proof mRNA vaccine manufacturing bases to accelerate clinical conversion, product registration and global vaccine commercial supply.
